Exciting Developments at Rosalind Franklin University
Rosalind Franklin University's Innovation and Research Park (IRP) has welcomed a new addition, the Northern Illinois Laboratory for Tolmar, Inc., a notable specialty pharmaceutical company. This new facility enhances Tolmar's ability to develop and commercialize essential pharmaceutical products while strengthening the university's industry collaboration.
About Tolmar and Its Impact
Founded in 2007, Tolmar has established itself as a global leader in long-acting injectable drug delivery systems. The company specializes in formulating and manufacturing these injectables particularly within urology, oncology, and endocrinology sectors. One of its primary products, utilized in advanced prostate cancer treatment, enjoys widespread distribution across 89 countries.
Expanding Operations and Capabilities
The new research facility at Rosalind Franklin University's IRP is designed to work synergistically with Tolmar's existing operations in Colorado. This expansion signifies a strategic advancement in Tolmar's presence in the Midwest while highlighting the commitment to innovation and excellence in drug development.
Insights from Tolmar's Leadership
Dr. Dave Loffredo, Tolmar's vice president of innovation, expresses enthusiasm about their new Illinois location, viewing it as a perfect fit. He emphasizes the value of being part of a vibrant research ecosystem at Rosalind Franklin, which aligns with their goal to foster scientific advancements.
Collaborative Opportunities Awaits
Dr. Stace Porter, the senior vice president of development operations for Tolmar, emphasizes the lab's potential for collaboration. He highlights the benefits of being situated in a region abundant with life science companies, expressing optimism about future innovations arising from both synergy and shared goals.
Facilities and Research Centers
Rosalind Franklin University's Innovation and Research Park features a state-of-the-art 100,000-square-foot facility that accommodates six prominent RFU research centers, including the Center for Cancer Cell Biology, Immunology, and Infection. This modern infrastructure presents an ideal environment for research collaborations that can dynamically propel biotechnology and pharmaceutical advancements.
Anticipated Collaborative Effects
RFU’s Executive Vice President for Research, Dr. Joseph DiMario, conveys the university's excitement about welcoming Tolmar into its ecosystem. He foresees fruitful collaborations leading to rapid advances in product development and innovation.
About Tolmar
Tolmar operates as a fully integrated specialty pharmaceutical organization, proficient in developing, manufacturing, and commercializing specialty drugs across diverse therapeutic areas such as oncology, urology, and endocrinology. Their facilities in Northern Colorado highlight Tolmar's commitment to producing specialized medical solutions.
About Rosalind Franklin University
Rosalind Franklin University is a pioneering institution dedicated to the spirit of innovation, paying homage to Dr. Rosalind Franklin's legacy. The university is recognized for its research achievements spanning several areas, including neuroscience, diabetes, and more, providing a strong foundation for collaborative research with companies like Tolmar.
Frequently Asked Questions
What is the purpose of Tolmar's new laboratory?
The laboratory aims to expand Tolmar's pharmaceutical development capabilities and enhance innovation opportunities.
How does this collaboration benefit both Tolmar and Rosalind Franklin University?
This partnership fosters a dynamic research environment, leading to accelerated product development and advancements in the pharmaceutical field.
When was Tolmar founded?
Tolmar was established in 2007 and quickly gained recognition in the pharmaceutical industry.
Where are Tolmar’s other operations located?
Besides the new facility in Illinois, Tolmar maintains its primary operations in Northern Colorado.
What types of pharmaceuticals does Tolmar specialize in?
Tolmar specializes in long-acting injectables, primarily targeting urology, oncology, and endocrinology therapies.
